Business Description
China Pharma Holding Inc
NAICS : 325412
SIC : 2834
ISIN : US16941T4013
Total Employee Number:
221Compare
Compare
Traded in other countries / regions
CPHI.USAXQJ.Germany Index Membership
NASDAQ Golden Dragon China Index IPO Date
2002-04-14Description
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -2.97 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.32 | |||||
Beneish M-Score | -4.27 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -76.8 | |||||
3-Year EBITDA Growth Rate | 64.7 | |||||
3-Year EPS without NRI Growth Rate | 73.3 | |||||
3-Year Book Growth Rate | -62.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.04 | |||||
9-Day RSI | 46.22 | |||||
14-Day RSI | 48.25 | |||||
3-1 Month Momentum % | 53.33 | |||||
6-1 Month Momentum % | 74.27 | |||||
12-1 Month Momentum % | -22.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.26 | |||||
Quick Ratio | 0.08 | |||||
Cash Ratio | 0.04 | |||||
Days Inventory | 165.08 | |||||
Days Sales Outstanding | 20.76 | |||||
Days Payable | 75.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -369.5 | |||||
Shareholder Yield % | -0.37 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 11.75 | |||||
Operating Margin % | -111.86 | |||||
Net Margin % | -114.31 | |||||
EBITDA Margin % | -34.88 | |||||
FCF Margin % | -5.6 | |||||
OCF Margin % | -3.58 | |||||
ROE % | -20.2 | |||||
ROA % | -14.87 | |||||
ROIC % | -13.35 | |||||
3-Year ROIIC % | 4.26 | |||||
ROC (Joel Greenblatt) % | -105.6 | |||||
ROCE % | -18.83 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 3.26 | |||||
PS Ratio | 3.08 | |||||
PB Ratio | 1.17 | |||||
EV-to-EBIT | -11.08 | |||||
EV-to-EBITDA | -35.53 | |||||
EV-to-Revenue | 12.39 | |||||
EV-to-FCF | -221.43 | |||||
Price-to-GF-Value | 6.12 | |||||
Price-to-Projected-FCF | 1.68 | |||||
Price-to-Median-PS-Value | 3.47 | |||||
Earnings Yield (Greenblatt) % | -9.03 | |||||
FCF Yield % | -0.49 | |||||
Forward Rate of Return (Yacktman) % | -2624.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CPHI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
China Pharma Holding Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.914 | ||
| EPS (TTM) ($) | -0.329 | ||
| Beta | 0.3995 | ||
| 3-Year Sharpe Ratio | -0.63 | ||
| 3-Year Sortino Ratio | -0.85 | ||
| Volatility % | 117.16 | ||
| 14-Day RSI | 48.25 | ||
| 14-Day ATR ($) | 0.52885 | ||
| 20-Day SMA ($) | 1.2145 | ||
| 12-1 Month Momentum % | -22.26 | ||
| 52-Week Range ($) | 0.3818 - 19.19 | ||
| Shares Outstanding (Mil) | 43.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China Pharma Holding Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
China Pharma Holding Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-12-30 08:00 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 1.09 (+1.87%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.24 (+41.10%) | ||
| Annual report for 2025 | 2026-04-01 | 0.61 (+1.67%) | ||
| General meeting for 2024 | 2025-12-30 08:00 | 1.24 (+2.48%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.57 (-1.26%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.48 (-0.67%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 2.10 (-5.83%) | ||
| 0.1:1 Stock Split | 2025-04-15 | 1.40 (-0.92%) |
Show
Entries
China Pharma Holding Inc Frequently Asked Questions
What is China Pharma Holding Inc(CPHI)'s stock price today?
The current price of CPHI is $1.04. The 52 week high of CPHI is $19.19 and 52 week low is $0.38.
When is next earnings date of China Pharma Holding Inc(CPHI)?
The next earnings date of China Pharma Holding Inc(CPHI) is 2026-11-12 Est..
Does China Pharma Holding Inc(CPHI) pay dividends? If so, how much?
China Pharma Holding Inc(CPHI) does not pay dividend.
Guru Commentaries on AMEX:CPHI
No articles.
Press Release
Articles on China Pharma Holding Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers